Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Phase 2
Completed
Conditions
First Posted Date
2004-08-05
Last Posted Date
2011-11-30
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT00089050
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

First Posted Date
2004-08-04
Last Posted Date
2011-03-07
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
3
Registration Number
NCT00003661
Locations
🇺🇸

North Shore University Hospital, Manhasset, New York, United States

🇺🇸

Nemours Children's Clinic, Jacksonville, Florida, United States

🇺🇸

Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States

and more 14 locations

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

First Posted Date
2004-08-04
Last Posted Date
2011-03-07
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
90
Registration Number
NCT00003662
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

🇺🇸

St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States

🇺🇸

University of Florida Health Science Center, Gainesville, Florida, United States

and more 12 locations

Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2
Conditions
First Posted Date
2004-07-29
Last Posted Date
2013-12-19
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
25
Registration Number
NCT00002688
Locations
🇳🇱

Academisch Medisch Centrum, Amsterdam, Netherlands

🇳🇱

Academisch Ziekenhuis Groningen, Groningen, Netherlands

🇳🇱

Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

and more 9 locations

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

First Posted Date
2004-07-14
Last Posted Date
2016-11-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
720
Registration Number
NCT00087581
© Copyright 2024. All Rights Reserved by MedPath